Sesen Bio Inc

Sesen Bio — Corporate Update (June 2019)

47 slides from Sesen Bio's corporate update, Jun 10, 2019

  1. Slide 1: June 2019 Regulatory Update

    June 2019 Regulatory Update NASDAQ SESN June 10, 2019

  2. Slide 2: Forward-Looking Statements

    FORWARD - LOOKING STATEMENTS This presentation contains forward - looking statements that involve substantial risks and uncertainties . All statements, other than statements of historical facts, contained in this presentation, including statements regarding our strategy, future operations, clinical

  3. Slide 3: Our Path Forward Starts with the Patient Journey

    OUR PATH FORWARD STARTS WITH THE PATIENT JOURNEY 3 “ Radical cystectomy is associated with significant morbidity and mortality and a negative impact on quality of life, and many patients actually refuse or are ineligible for cystectomy. ” 2 1 US National Library of Medicine National Institutes of He

  4. Slide 4: 2019 Outlook

    2019 Outlook 4 March 31, 2019 March 31, 2018 Cash and Cash Equivalents $42.4M $19.7M Cash runway into 2020, with no outstanding debt • As of 6/7/2019: $3.4M in additional cash proceeds from shares issued pursuant to warrant exercises* Recent milestones with FDA Type of FDA Meeting Completed Meeting

  5. Slide 5: 2019 Regulatory Update for Vicinium for NMIBC

    2019 Regulatory Update for Vicinium for NMIBC 5 May 20 th Type C CMC Meeting: FDA Accepts Analytical Comparability Plan to Support the BLA and Commercialization of Vicinium for NMIBC • Reached alignment with FDA on primary objective of meeting: acceptance of analytical comparability plan for commerc

  6. Slide 6: Alignment with FDA guidance on program

    Source: FDA Guidance: BCG - Unresponsive Non - muscle Invasive Bladder Cancer: Developing Drugs and Biologics for Treatment Guidance for Industry, February 2018 CRR is Complete Response Rate, DoR is Duration of Response, BCG is bacillus Calmette - Guérin, WHO is World Health Organization 6 Our long

  7. Slide 7: Totality of Phase III data suggest strong benefit-risk profile

    We believe the totality of Phase III data suggest a strong benefit - risk profile 7 Endpoint How Endpoint is Measured Preliminary Results Complete Response Rate (CRR) Primary Endpoint CIS patients Defined as the proportion of patients who show no evidence of high - risk disease, or disease progressi

  8. Slide 8: Duration of Response: probability of maintaining CR

    Duration of Response: For patients treated with Vicinium for three months, at each time point a CR is confirmed, the probability of maintaining a CR increases 8 15% 43% 54% 68% 0% 20% 40% 60% 80% Day 0 CR at 3 months CR at 6 months CR at 9 months Probability of Maintaining Complete Response for at L

  9. Slide 9: Complete and Partial Response in Phase II

    9 Complete and Partial Response: In our Phase II clinical trial, 83% of patients had a complete or partial response Start of Treatment with Vicinium 3 - Month Response ~40% of patients had a complete response ~43% of patients had a partial response ~17% of patients have no response *Note: D ata refe

  10. Slide 10: Global BCG shortage expected to last through 2019

    Latest global BCG shortage expected to last at least through remainder of 2019 10 2012 2013 2014 2015 2016 2017 2018 2019 Sanofi suspends production of BCG Connaught strain during facility renovations Merck announces shortages of BCG Tice strain Sanofi discontinues all global production of BCG Conna

  11. Slide 11: Vicinium may be cystectomy-sparing

    We believe our Phase III data suggests Vicinium may be cystectomy - sparing by significantly delaying or avoiding cystectomy for patients 11 Your Bladder: A Hero Organ Radical Cystectomy: Life - Altering Surgery ▪ Self - controlled storage organ in the body ▪ Holds urine for release so the body is n

  12. Slide 12: June 2019 Company Highlights

    June 2019 Company Highlights 1. Positive interactions with FDA on May 20 th and June 6 th resulting in greater confidence in our regulatory and commercial pathway 2. Long - term relationship with the FDA enables high level of alignment with regulatory guidelines 3. Vicinium appears to demonstrates c

  13. Slide 13: Additional Information

    Additional Information e sesen 13

  14. Slide 14: Addendum Table of Contents

    ADDENDUM TABLE OF CONTENTS 1. Updated Phase III data further demonstrate a compelling benefit - risk profile * 2. Strong regulatory and commercial rationale 3. Manufacturing process expected to be reliable and inexpensive 14 *Updated Phase III data are as of the March 1, 2019 data cut

  15. Slide 15: Vicinium targets cancer cells selectively

    • Antibody fragment (scFv) targeting EpCAM linked to a cytotoxic payload (Pseudomonas exotoxin A) to form a single protein • EpCAM over - expressed in cancer cells • Highly selective targeting of cancer cells while generally avoiding normal cells • Inhibits protein synthesis, and kills both rapidly

  16. Slide 16: Vicinium: Dual Mechanism of Action

    T cells recognize neoantigen and kill cancer cells T cell proliferation Ligand DAMPS “Find signal” Neoantigen release “Eat signal” Vicinium causes immunogenic cell death by triggering damage - associated molecular patterns (DAMPs) Vicinium selectively targets EpCAM Induction of immunogenic cell deat

  17. Slide 17: Strong benefit-risk profile in Phase III Trial

    : Vicinium demonstrates a strong benefit - risk profile in our Phase III Trial 17 Benefit Risk Safety and Tolerability Selectively targets cancer cells while generally avoiding healthy cells Favorable profile relative to BCG, Valstar , checkpoint inhibitors No dose or age - related increase in AEs I

  18. Slide 18: Complete Response Rate: Phase II and III consistent

    Complete Response Rate: Our Phase II and Phase III clinical trials are highly consistent for Complete Response Rate 18 40% 27% 18% 16% 39% 28% 21% 15% 0% 10% 20% 30% 40% 50% 3-Month CRR 6-Month CRR 9-Month CRR 12-Month CRR Complete Response Rate (CRR) in Carcinoma in situ Patients % of Patients with

  19. Slide 19: Duration of response definition and results

    19 Duration of response is defined as the time of complete response to treatment failure. *Not Estimable, the upper bound for the 95% confidence interval has not reached the median. **Note: Data reflect an ad hoc analysis of pooled results of patients in cohorts 1&2. Median duration of response for

  20. Slide 20: Duration of Response by BCG exposure

    Duration of Response : Vicinium is generally more efficacious in CIS patients treated with less BCG 20 Note: Data reflected consists of Cohorts 1&2 patients (n=93) *Not Estimable, the upper bound for the 95% confidence interval has not reached the median. PIII CIS Patients Median 100 80 60 40 20 0 %

  21. Slide 21: Time to Disease Recurrence in papillary patients

    21 Time to Disease Recurrence: For high - risk papillary patients who were treated with Vicinium, 50% are disease - free at 1 year Time to disease recurrence: defined as the time from the date of the first dose of study treatment to treatment failure. *Not Estimable, the upper bound for the 95% conf

  22. Slide 22: Time to Cystectomy

    Time to Cystectomy: The average patient remains cystectomy - free for 854 days (~28 months) after treatment with Vicinium 22 Time to cystectomy: defined as the time from the date of first dose of study treatment to surgical bladder removal. Data refl ect ed consist of patients from all cohorts 1, 2

  23. Slide 23: Key Survival Endpoints

    Key Survival Endpoints: Early survival data is encouraging regarding health outcomes for patients treated with Vicinium 23 PIII All Cohorts Progression - free survival: defined as the time from the date of first dose of study treatment to disease progression (i.e. T2 or more advanced disease) or dea

  24. Slide 24: Safety and Tolerability: adverse events in Phase III

    24 Treatment - Related AEs (% patients) All AEs (% patients) Any AE Urinary tract infection Dysuria Hematuria Pollakiuria (frequency of urination) Fatigue Diarrhea Micturition urgency Nausea Lipase increased Safety and Tolerability: In our Phase III trial, AEs were generally low grade and resulted i

  25. Slide 25: Safety and Tolerability: Phase II and III consistent

    Safety and Tolerability: Our Phase II and Phase III clinical trials are highly consistent for safety and tolerability 25 Category Phase II (n=46) Phase III (n=133) Any AE 43 (94%) 117 (88%) Grade 3 - 5 AEs 9 (20%) 29 (22%) Treatment - related AEs 30 (65%) 65 (49%) Treatment - related Grade 3 - 5 AEs

  26. Slide 26: Phase III Trial: Patient Demographics

    Phase III Trial: Patient Demographics CHARACTERISTICS COHORT 1 COHORT 2 COHORT 3 CIS that recurred within 6 months of adequate BCG (Refractory) CIS that recurred >6 months but ≤11 months of adequate BCG (Relapsing) Papillary tumors (without CIS) that recurred within 6 months of adequate BCG Total pa

  27. Slide 27: Phase III Data Tables by Cohort for CIS

    Phase III Trial: Data Tables by Cohort for Carcinoma in situ 27 Cohort 1 (n=86) Complete Response Rate Time Point Evaluable Patients Complete Response Rate (95% Confidence Interval) 3 - months n=86 37% (27% - 48%) 6 - months n=86 26% (17% - 36%) 9 - months n=85 19% (11% - 29%) 12 - months n=84 15% (

  28. Slide 28: Additional Vicinium Clinical Data

    Additional Vicinium Clinical Data 28 Preliminary Phase II vs. Phase III Complete Response Rate Time Point Phase II Pooled CRR (95% Confidence Interval) Phase III Pooled CRR (95% Confidence Interval) 3 - months 40% (26% - 56%) 39% (29% - 49%) 6 - months 27% (15% - 42%) 28% (19% - 38%) 9 - months 18%

  29. Slide 29: CRR 95% confidence interval vs Valstar

    Complete Response Rate: We believe our 95% confidence interval rules out the CRR for Valstar and a clinically unmeaningful CRR 29 FDA Guidance: For single - arm trials of patients with BCG - unresponsive NMIBC in patients with CIS that use complete response rate as the primary endpoint, the lower bo

  30. Slide 30: No age-related increase in adverse events

    Safety and Tolerability: No age - related increase in adverse events in our Phase III trial 30 Note: Data reflected consist of patients from all cohorts 1, 2 & 3 (n=133) as of March 1, 2019 data cutoff . Mean AEs for all patients: 4.6 (range 0 - 26), Mean treatment - related AEs for all patients: 1.

  31. Slide 31: Addendum Table of Contents

    ADDENDUM TABLE OF CONTENTS 1. Updated Phase III data further demonstrate a compelling benefit - risk profile 2. Strong regulatory and commercial rationale 3. Manufacturing process expected to be reliable and inexpensive 31

  32. Slide 32: Bladder cancer is highly prevalent with unmet medical need

    • $4B+ in annual treatment costs for bladder cancer in the US alone 2 • 75 - 85% diagnosed as NMIBC 3 • Limited treatment options for high - risk NMIBC - Only three approved treatments in the last 100 years - BCG remains standard - of - care in many countries • 50% patients fail within the 1 st year

  33. Slide 33: Carcinoma in situ: most difficult form of NMIBC to treat

    Carcinoma in situ : the most difficult form of NMIBC to treat 33 Note: Diagram is for illustrative purposes (Carcinoma in situ ) Normal inner lining • Field change disease often involving the entire bladder lining that is very difficult to treat • Failed on two or more courses of BCG, which is the g

  34. Slide 34: Significant unmet need for innovative therapies in NMIBC

    Significant unmet need for innovative medical therapies to treat NMIBC 34 Product FDA Approval Additional Product Information Thiotepa 1959 Rarely used in current treatment regimens BCG* 1989 (Tice) Recommended first line treatment Surgery: Radical Cystectomy Recommended second line treatment Valsta

  35. Slide 35: Radical cystectomy remains recommended option after BCG failure

    Radical cystectomy remains recommended treatment option after BCG failure 35 • Complex, long surgical procedure (10+ hours) • Significant rates of morbidity (30 - 60% within 90 days) and mortality (2 - 9% within 6 months) 2 – 64% complication rate within 90 days 3 – ~35% of patients require ER visit

  36. Slide 36: Bladder cancer patient experience among the poorest

    Patient surveys have shown that the experience of those with bladder cancer is one of the poorest 1 36 Treatment Options 86 72 68 75 65 47 0 10 20 30 40 50 60 70 80 90 Category 1 Category 3 Category 2 Key Drivers of Poor Patient Journey in Bladder Cancer vs. Average Experience Among 5 Most Common Ca

  37. Slide 37: Virtuous Cycle: key segments are advocates

    Virtuous Cycle: High possibility that all three key segments are advocates & take action 37 Sources: Sesen Bio internal market research: Patient Journey Insights, Blue Print qualitative study May 2018, n=24; Sesen Market Oppor tun ity, Monitor Deloitte qualitative and quantitative (n=34) study Octob

  38. Slide 38: Vicinium provides continuity of care

    BCG TREATMENT VICINIUM TREATMENT 2 - hour infusion, hold, and rotation Administration through urinary catheter Treated by Urologist (same Urologist) Medical support team throughout care (same team) Response assessment every 3 months V icinium as potential to provide continuity of care for patients w

  39. Slide 39: Addressable Market (US)

    Addressable Market (US) 39 Annual Volume ~80K 1 Patients diagnosed with bladder cancer Patients diagnosed with NMIBC CIS: ~20% 2 Sources: 1 National Cancer Institute, SEER Cancer Stat Facts: Bladder Cancer, 2017. 2 Therapeutic Advances in Urology. Best Practices in the Treatment of Non - muscle Inva

  40. Slide 40: ~1,500 Urologists treat 75% of patients

    0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 0 200 400 600 800 1,000 1,200 1,400 1,600 1,800 2,000 2,200 2,400 2,600 2,800 3,000 3,200 3,400 3,600 3,800 4,000 4,200 4,400 4,600 4,800 BCG Prescribers Prescribers Only ~1,500 Urologists account for the bulk of NMIBC treatment and are concentrated in gro

  41. Slide 41: Pricing and Reimbursement (US)

    Pricing and Reimbursement (US) 41 Price Reference (Annual Cost) 1 $200K $0K Sources: 1 Center for Medicare and Medicaid Services (CMS) Average Selling Price (ASP) Price List. CI price benchmarks are based on Keyt rud a, Opdivo and Tecentriq . 2 Payer Interviews, ClearView Analysis, n=10, March 2019.

  42. Slide 42: OUS opportunity for Vicinium larger than US

    We estimate the OUS opportunity for Vicinium is 2 - 3 larger than the US 42 Geography Est. Incidence Relative to U.S. 1 Est. Price Relative to U.S. 2 EU5 1.2 – 1.4 0.50 – 0.71 Japan 0.4 – 0.6 0.60 – 0.70 Rest of Europe (Not including EU5) 1.0 – 1.2 0.60 – 1.10 North America (Not including U.S.) 0.1

  43. Slide 43: Addendum Table of Contents

    ADDENDUM TABLE OF CONTENTS 1. Updated Phase III data further demonstrate a compelling benefit - risk profile 2. Strong regulatory and commercial rationale 3. Manufacturing process expected to be reliable and inexpensive 43

  44. Slide 44: Manufacturing of Vicinium reliable and inexpensive

    Manufacturing of Vicinium is expected to be reliable and inexpensive Cell Bank 2000 L Production Bioreactor 5: Q - Sepharose HP 5 Column P urification Shake flask Centrifugation (bulk solids removal) Filtration (MF for fine solids removal and UF/DF for buffer exchange) DP Fill Finish (7 mL @ 5mg/mL)

  45. Slide 45: Vicinium Comparability Strategy

    Vicinium Comparability Strategy * Guidance “If a manufacturer can provide assurance of comparability through analytical studies alone, nonclinical or clinical studies with the post - change product are not warranted.” 1 Sesen’s analytical comparability plan is comprised of 4 key elements: 1. Analyti

  46. Slide 46: Experienced partners for global manufacturing and supply

    » Licensed for commercial production of 8 approved products » 25+ years developing and manufacturing biologics » 310+ protein - based therapeutics in development and / or manufacturing » Proven track record with FDA and worldwide regulatory agencies Baxter’s BioPharma Solutions Business: » 160 clini

  47. Slide 47: Vicinium: A single cGMP Manufacturing Process

    Vicinium : A single cGMP Manufacturing Process 47 Bioreactor Purification (Generates Drug Substance) Fill/Finish (Generates Drug Product) Bioreactor ( mAb production) Purification ( mAb intermediate) Fill/Finish (Generates Drug Product) Vicinium cGMP manufacturing process producing a single fusion p

Sesen Bio — Corporate Update (June 2019) on 6ix